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IranReceived 4 January 2014; received in revised form 30 April 2014; accepted 19 May 2014; online published-ahead-of-print 30 June 2014Background The purpose of this study was to determine whether endogenous atrial natriuretic peptide (ANP) con-
tributes to the protective effect of neurohypophysial hormone oxytocin (OT) in heart preconditioning.
Methods Sprague–Dawley male rats were subjected to 25 min regional ischaemia and 120 min reperfusion and were
divided into eight groups. Oxytocin or an equivalent volume of saline was administrated intraperitoneally,
30 min before ischaemia. The OT receptor antagonist (atosiban), ANP receptor antagonist (anantin) and
nitric oxide synthase inhibitor (L-NAME) were injected 10 min before OT. In other groups, atosiban, anantin
and L-NAME were only administered 40 min prior to ischaemia.
Results Compared with the ischaemia/reperfusion group (I/R), alterations in infarct size, biochemical parameters
[LDH (lactate dehydrogenase), CK-MB (creatine kinase-MB), MDA (malondialdehyde) plasma levels] and
severity of ventricular arrhythmia due to I/R injury were attenuated and VF was abolished by OT treatment.
These OT effects were eliminated by OT and ANP receptor blockers and nitric oxide synthase inhibitor, but
anantin did not reverse the effect of OT in lipid peroxidation.
Conclusions These findings demonstrate an important contributory role of ANP in the OT induced protection in
myocardial ischaemia reperfusion. OT also reduced lipid peroxidation with a NO-dependent mechanism.
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Oxytocin, neurohypophyseal nonapeptide hormone, plays
important roles in regulation of blood pressure, vascular
tone and cardiovascular function [1]. Oxytocin is also syn-
thesised in cardiac myocytes and exerts important cardio-
vascular effects directly via action on its receptors [2], which
are coupled to G proteins [1].
Previous study has shown that hormone preconditioning
with OT protects the heart against ischaemia and OT receptors
contribute to the process of cardioprotection [3]. The cardio-
protective effect of OT may include direct effects on the ischae-
mic myocardium. It may also indirectly impact the release of© 2014 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) a
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was based on the observations that OT via neuroendocrine/
endocrine/ paracrine pathways release ANP from the heart,
which then exerts a negative chrono- and inotropic effect via
activation of guanylyl cyclase and release of cGMP [4–6].
Natriuretic peptides are important factors involved in the
regulation of hydroelectrolyte balance and vascular tone,
inducing hypotension, natriuresis and diuresis as well as car-
dioprotection in myocardial ischaemia both as circulating hor-
mones and as local autocrine and/or paracrine factors [7]. ANP
exerts its biological actions through, and the interaction with,
two specific membrane-bound guanylyl cyclase receptors:
natriuretic peptide receptor A (NPR-A) and B (NPR-B) [8].nd the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier
niversity of Medical Sciences, Tehran, Islamic Republic of Iran.
ANP involvement in OT protection 87On the other hand, recent evidence demonstrated that the ANP
exerts its vasodilatory action through nitric oxide (NO) gener-
ation [9].
As oxytocin and ANP act in concert to control vascular
homeostasis and the body’s internal environment, it is pos-
sible that the protective effect of OT is mediated through
endogenous ANP; therefore, the purpose of this study was to
determine whether endogenous ANP contributes to the pro-
tective effect of OT in the preconditioning of the heart. To test
this hypothesis, we used the competitive NPR-A antagonist
anantin to block any ANP-mediated effect. The reason for
this was due to the fact that ANP exerts its cardioprotective
effects by means of NPR-A/ cGMP pathway [7].
Haemodynamic parameters, infarct size, biochemical
indexes as well as the ventricular arrhythmia assessments
were used to evaluate the effects.Materials and Methods
Animals
Male Sprague–Dawley rats weighing 280–310 g, were main-
tained under controlled conditions (temperature 20–22 8C,
humidity 40–50% and 12 hrs light- dark cycle), fed on a
standard diet with free access to water. All experimental
procedures were carried in accordance with the institutional
guidelines of Tehran University of Medical Sciences (Tehran,
Iran).
Surgical Preparation
The animals were anaesthetised with sodium pentobarbital
(60 mg/kg, i.p.). After tracheal intubation, artificial respira-
tion with room air-and-oxygen mixture was instituted by use
of a rodent ventilator (model 683, Harvard Apparatus) with a
stroke volume of approximated 1.2 ml 100 g1 body weight
at a rate of 60–70 stroke min1. The right carotid artery was
cannulated for blood sampling and cardiac monitoring
throughout the experiment, using a computerised data
acquisition system (ML750 PowerLab/4sp, ADInstruments).
A left thoracotomy was performed at the fourth intercostal
space followed by a pericardiotomy. A 6-0 silk suture was
passed below the left anterior descending coronary artery
(LAD) for later induction of coronary artery occlusion. After
25 min, the suture was removed, and animals were reper-
fused for 120 min. Heart rate and blood pressure were sta-
bilised for 10 min before the following protocols were
initiated. At the end of 120 min reperfusion, infarct size
and myocardial enzyme leakage were measured.
Experimental Protocol
The animals were divided into eight groups. (i) The control
group (cardiac I/R): following a 10 min stabilisation period,
rats (n = 10) were submitted to 25 min of ischaemia, 120 min
reperfusion. Saline was administered i.p. 30 min before
hearts were subjected to LAD occlusion. (ii) Oxytocin treated
group: six animals received oxytocin (Sigma Chemical Co.
St. Louis, MO, USA) 0.01 mg/rat [3], 30 min before ischaemia.(iii) Atosiban treated group (ATO + OT, n = 6); this group
was pretreated with OT-receptor antagonist, atosiban
(0.5 mg/rat, i.p., Sigma Chemical Co. St. Louis, MO, USA)
10 min before OT. (iv) Anantine treated group (ANA + OT,
n = 7): anantin (1.2 mg/kg, i.p., Sigma Chemical Co.
St. Louis, MO, USA) was administrated 10 min before OT
to explore the role of ANP receptor-mediated in OT-cardio-
protection. (v) L-NAME treated group (L-NAME + OT,
n = 7): this group received 0.2 mg/kg nitric oxide synthase
inhibitor (Sigma Chemical Co. St. Louis, MO, USA), intra-
peritoneally 10 min prior to the OT treatment.
In (vi) ATO (n = 7), (vii) L-NAME (n = 8) and (viii) ANA
(n = 8) groups alone, inhibitors were used 40 min prior to
LAD occlusion.
Haemodynamic Variables
Arterial blood pressure and heart rate (HR) were continu-
ously monitored and recorded throughout the experiment;
15 min baseline, preocclusion, 25 min LAD occlusion, and
120 min reperfusion. At the same time-points, the rate pres-
sure product (RPP), systolic blood pressure multiplied by the
heart rate, also were calculated by the data acquisition
system.
Area at Risk and Myocardial Infarct Size
Determination
The area at risk (ischaemic-reperfused region) and the infarct
size were measured using Evans blue and 2,3,5- triphenylte-
trazolium chloride double staining method (TTC). In brief,
LAD was reoccluded and 2 ml of a 2% Evans blue solution
was injected via the tail vein at the end of 120 min reperfu-
sion. Then, the heart was removed, and immediately frozen
at -20 8C. To define infarct size, hearts were sliced trans-
versely then stained in triphenyltetrazolium chloride (TTC,
in 0.1 M phosphate buffer, pH 7.4) at 37 8C for 15 min, fol-
lowed by incubation in 10% formalin for 24 h to increase
contrast. Total area at risk was expressed as a percentage of
the left ventricles (AAR/LV). The infarct size was deter-
mined as the ratio between the pixel of necrotic area (NA)
and ischaemic area at risk (AN/AAR), using Adobe
Photoshop 7.0.
Biochemical Analysis
At the end of reperfusion period, blood samples were col-
lected to measure the myocardial enzyme leakage, including
lactate dehydrogenase (LDH), creatinine kinase (CK-MB)
and malonyldialdehyde (MDA). The heparinised blood sam-
ples were centrifuged and obtained plasma was analysed by
using an autoanalyser (Roche Hitachi Modular DP Systems,
Mannheim, Germany) for determination of CK-MB and LDH
levels, MDA was determined by spectrophotometrically.
Arrhythmia Analysis
Electrocardiograms (ECGs) were continuously monitored
with standard limb lead-II throughout the experiment.
Both ischaemia and reperfusion induced ventricular arrhyth-
mias were determined in accordance with the Lambeth
88 F. Houshmand et al.Conventions [10]. Premature ventricular contractions (PVC)
were defined as identifiable premature QRS complexes. Ven-
tricular tachycardia (VT) was defined as four or more conse-
cutive premature ventricular contractions (PVC). Ventricular
fibrillation (VF) was defined as a signal that changed from
beat to beat in rate and configuration or where individual
QRS-deflections could not easily be distinguished from one
another. The severity of arrhythmias was quantified by the
following scoring system [11] 0: <10 PVC, 1: 10 PVC, 2: VT
(duration <30 s), 3: VT (duration 30 s), 4: VF starting 15 min
after the onset of ischaemia, 5: VF starting 5–15 min after the
onset of ischaemia, 6: VF starting within 5 min after the onset
of ischaemia.
Statistical Analysis
All data were presented as mean  SEM or the percentage of
incidence. The repeated measures ANOVA were used to
compare the haemodynamic parameters within groups.
One-way ANOVA followed by the Duncan’s test was used
to compare differences in haemodynamic parameters, infarct
size, CK-MB, LDH and MDA plasma content between
groups. P < 0.05 was considered statistically significant.Results
Haemodynamic Variables
There were no significant differences among groups at the
baseline before treatment. In control animals (I/R group),
coronary occlusion decreased RPP significantly (P < 0.05).
During 120 min of reperfusion, systolic arterial pressure
(SAP) and RPP reduced (P < 0.05) without a significant
changes in the heart rate.
Before coronary artery occlusion, neither atosiban nor
anantine nor L-NAME pretreatment influenced significantlyTable 1 Haemodynamic values.
Group Basal OT 
SAP HR RPP SAP HR RPP 
Control 116  7 366  12 43  3 
OT 126  8 363  8 46  2 132  5 360  10 47  
ATO + OT 115  2 345  11 40  1 124  4 320  7 40  
ANA + OT 124  5 360  10 45  3 128  7 340  2y 44  
L-NAME + OT 123  5 341  14 42  3 130  5 334  8 43  
ATO 117  5 350  8 41  2 
ANA 121  4 345  11 42  3 
L-NAME 124  5 355  12 44  2 
SAP (systolic arterial pressure, mmHg), HR (heart rate, beats/min), RPP (rate press
(anantin). Values are presented as the mean  SEM.
yP < 0.05, vs. baseline within the same group.
*P < 0.05 vs. control,
P < 0.05, vs. OT.the haemodynamic parameters in comparison with the base-
line (data not shown). Anantin (ANA + OT group) induced a
significant reduction in HR as compared to baseline when OT
was administrated (P < 0.05, Table 1).
In the OT group, ischaemia had nearly no influence on
haemodynamic variables except for SAP which was signifi-
cantly increased compared to the control group, after a
120 min reperfusion period (P < 0.05). Pretreatment with
anantin (ANA+OT group) significantly decreased HR and
RPP during ischaemia/reperfusion compared to their base-
line. It also had significantly reduced SAP during reperfu-
sion. As compared to OT group, anantin induced significant
reduction in HR during ischaemia. As shown in Table 1, L-
NAME (L-NAME + OT) caused significant increase in RPP
and SAP during reperfusion; anantin (ANA + OT) and ato-
siban (ATO + OT) also significantly enhanced SAP compared
to control this time period. No significant differences of
haemodynamic parameters were observed in other groups.
Area at Risk and Infarct Size
Measurements
Fig. 1 represents the area at risk (AAR/LV) and the necrotic
area (NA/AAR) as a percentage of area at risk. There were no
significant differences in the area at risk among groups.
Oxytocin significantly reduced myocardial infarction com-
pared with control group (P < 0.05). This protective effect
was totally abolished by atosiban, anantin and L-NAME.
Treatment with atosiban, anantine and L-NAME alone had
no significant effect on infarct size compared to I/R group.
Biochemical Analysis
Compared to the control group, administration of OT could
prevent elevation of LDH and CK-MB activity in plasma after
ischaemia reperfusion injury. This reduction was signifi-
cantly abolished by atosiban, anantin and L-NAMEIschaemia Reperfusion
SAP HR RPP SAP HR RPP
104  10 349  16 37  4y 89  7y 324  15 31  3y
3 128  8 358  13 43  5 116  6* 338  16 38  3
1 117  7 320  10 37  3 115  5* 322  8 37  2
4 110  10 316  14y, 35  3y 118  5* 326  14y 39  2y
2 112  4 325  7 37  1 117  7* 339  13 40  3*
111  5 325  14 36  2 110  7 319  17 35  3
102  7 325  12 32  2 107  6 323  18 34  2
108  5 328  16 35  2 111  6 326  11 36  3
ure product, beat min1 mmHg  103). OT (oxytocin), ATO (atosiban), ANA
Figure 1 Myocardial area at risk (AAR/LV %) and necrotic area (NA/AAR %). OT (oxytocin), ATO (atosiban), ANA
(anantin) and L-NAME. The values are expressed as the mean  SEM.
*P < 0.05 vs. control, P < 0.05 vs. OT.
ANP involvement in OT protection 89administration. The level of LDH was significantly higher
than control group in L-NAME + OT group (Table 2).
Malonyldialdehyde (MDA) plasma level in OT treated
group was significantly reduced compared to control
group. When atosiban and L-NAME was administrated
before OT, the level of MDA was significantly increased,
but the anantin-receiving animals had MDA level similar
to those of the OT group. Inhibitor alone had no significant
effect on MDA, LDH and CK-MB plasma level compared
to I/R group.Table 2 Plasma levels of LDH, CK-MB and MDA at the
end of reperfusion.
Group LDH (U/L) CK-MB (U/L) MDA (nmol/ml)
Control 1836  215 2273.8  238 3.3  0.2
OT 850  75* 1462  138* 2.7  0.15*
ATO + OT 923  154 2604  365 3.3  0.2
ANA + OT 1979  145 2741  220 2.3  0.15*
L-NAME + OT 2239  160*, 2523  288 3.4  0.25
ATO 1064  109 2522  256 3.1  0.2
ANA 1996  155 2487  277 2.7  0.2
L-NAME 1916  155 2486  276 3.5  0.3
LDH (lactate dehydrogenase), CK-MB (creatine kinase-MB), MDA (mal-
ondialdehyde). OT (oxytocin), ATO (atosiban), ANA (anantin). The values
are expressed as the mean  SEM.
*P < 0.05, vs. control.
P < 0.05, vs. OT group.Ventricular Arrhythmias During
Ischaemia
In the control group, all rats experienced VT, while VF
occurred in 80% of the hearts, and the arrhythmias score
(AS) averaged 4.7  0.2.
In OT treated group, the total PVC and AS were signifi-
cantly decreased during occlusion period compared to the
control (P < 0.05). In addition, no ventricular arrhythmia (VT
and VF) was observed during ischaemia in the OT group.
Oxytocin and ANP receptor blockers in ATO+OT and
ANA + OT groups and nitric oxide inhibitor in L-NAME
+ OT group increased arrhythmias score and abolished the
cardioprotective effect of OT on arrhythmias (Figs. 2–4). The
number of episodes of VT in L-NAME + OT and duration of
VT in ANA + OT group was markedly enhanced compared
to ATO + OT group (Fig. 3).
The incidence of VT was 0% in the OT group and 100% in the
control, ATO + OT, ANA + OT and L-NAME + OT groups.
Compared with the control rats, OT abolished VF. Admin-
istration of atosiban, anantin and L-NAME prior to OT
increased the incidence of VF to 33.3% (P > 0.05), 57.2%
and 57.1% (P < 0.05) respectively, (vs. to 0% in OT). More-
over, duration of ventricular fibrillation (VF) in ANA + OT
group was markedly enhanced compared to control group
(Fig. 4). Atosiban, anantin and L-NAME alone had no signif-
icant effect on ventricular arrhythmias (Figs. 2–4).
Ventricular Arrhythmias During
Reperfusion
The duration of ventricular tachycardia (VT) in the OT group
was shorter than the other groups and only two out of six rats
Figure 2 Distribution of the score of arrhythmia and log10 PVC during ischaemia. OT (oxytocin), ATO (atosiban), ANA
(anantin). The values are expressed as the mean  SEM.
*P < 0.05 vs. control, P < 0.05 vs. OT, +P < 0.05 vs. ATO + OT.
Figure 3 Duration (s) and episode number of VT (ventricular tachycardia) during ischaemia. OT (oxytocin), ATO (atosiban),
ANA (anantin). The values are expressed as the mean  SEM.
*P < 0.05 vs. control, P < 0.05 vs. OT, +P < 0.05 vs ATO + OT.
90 F. Houshmand et al.had VT with a mean of 0.4  0.2 episodes. Rats pretreated with
OT experienced not only a significantly reduced PVC, but also
experienced a significant reduction in the AS (0.8  0.5) com-
pared with the control group.
The incidence of VT was significantly less in OT and ATO
+ OT groups than in L-NAME + OT group. The atosiban
(ATO + OT) group had fewer PVC than the L-NAME + OT
and ANA + OT groups. Both anantin and L-NAMEadministration before OT resulted in a marked increase in
the duration of VT (Table 3). Atosiban, L-NAME and anantin
by themselves had no significant effect on arrhythmias.
Discussion
In order to explore the mechanisms involved in the OT-
induced early preconditioning against ischaemia and
Figure 4 The incidence and duration of ventricular fibrillation (VF) during ischaemia. OT (oxytocin), ATO (atosiban), ANA
(anantin). The values are expressed as the mean  SEM.
*P < 0.05 vs. control, P < 0.05 vs. OT, +P < 0.05 vs. ATO + OT.
Table 3 The severity of arrhythmias during reperfusion.
Group Log10 PVC Duration of (s) Arrhythmia(s) Episode of Arrhythmias Incidence of (%) Arrhythmia Score
VT VF VT VF VT VF
Control 1.3  0.2 6  3 0  0 2  0 0  0 2  0
OT 0.6  0.1* 1.6  1.4 0  0 0.4  0.2 0  0 33.3 0 0.8  0.5*
ATO + OT 0.8  0.3 8.1  4 0  0 0.7  0.3 0  0 50 0 1.5  0.2
ANA + OT 1.7  0.3 16  9 6.9  6.9 3.4  2 0.4  0.4 71.4 14.3 3  0.3
L-NAME + OT 1.2  0.1 15.1  5 0  0 2  0.6 0  0 100,+ 0 2.1  0.1
ATO 0.8  0.2 9.4  3 0  0 1  0.4 0  0 71 0 1.7  0.2
ANA 1.5  0.2 11  5 5.7  3.7 3  0.8 0.7  0.5 57 25 2.3  0.5
L-NAME 1.4  0.2 16.3  5 0.9  0.9 2.4  0.7 0.1  0.1 86 14.3 2.4  0.3
PVC (premature ventricular contraction), VT (ventricular tachycardia), VF (ventricular fibrillation). OT (oxytocin), ATO (atosiban), ANA (anantin). Data are
presented as mean  SEM.
*P < 0.05 vs. control,
P < 0.05 vs. OT.
ANP involvement in OT protection 91ventricular arrhythmias in the rat heart in vivo, we investi-
gated the potential role of natriuretic peptide pathways. In
the present study, we found that blockade of the ANP recep-
tors by anantin, a competitive NPR-A antagonist [12], pre-
vented the cardioprotective properties of OT, indicating that
the ANP pathway plays a prominent role in OT-induced
cardiac protection. The involvement of NO in oxytocin
reduced lipid peroxidation was also determined.
Although there is evidence suggesting the protective role
for ANP against I/R injury in the heart, this is the first study
to our knowledge that shows a link between OT and ANP inthe regulation of protection on myocardial I/R injury. This is
also supported by a recent study which suggests the role of
the oxytocin-ANP system in cardiomyogenesis [13]. In a
recent study on diuresis and natriuresis effects of OT,
ANP pathway involvement was proposed [6]. Similarly,
others have demonstrated that OT plays an important role
in cardiovascular homeostasis by regulating blood volume
via ANP release from cardiac atria [5,6].
In the present study, OT significantly reduced I/R-induced
heart damage with lower changes of haemodynamic values
than those in control group. In spite of vasodilatory effects of
92 F. Houshmand et al.ANP, blockade of ANP receptor (NPR-A), in ANA + OT
group, had no effect on haemodynamic parameters before
induced occlusion, but significantly reduced these parame-
ters during I/R. In agreement with our results, Chowdrey
et al. [14] and Takata et al. [15] have demonstrated that ANP
has no significant influence on haemodynamic variables
when it was added before ischaemia.
The plasma level of LDH and CK-MB, associated with heart
ischaemia reperfusion injury, were also significantly lower
after reperfusion in the OT group than in the control group.
Furthermore, OT prevents lipid peroxidation in the ischaemic
reperfused myocardium. Malondialdehude (MDA), a bio-
marker of cardiac oxidative injury, is a product of lipid per-
oxidation that can be produced by a variety of oxidative
damages [16]. Biyikli et al. has been reported that OT reduces
oxidant renal injury in pyelonephritic rats by its antioxidant
actions [17].
In addition, OT exerts antioxidant effects on vascular
smooth muscle cells, aortic ECs, and macrophages through
attenuation of NADPH-oxidase-dependent superoxide pro-
duction [18]. The antioxidant ability of OT was also respon-
sible for the renoprotective properties of OT [19].
In our study, unlike increased LDH and CK-MB levels, the
plasma level of MDA was not significantly changed by anan-
tin, as compared to OT. Therefore, possibly other signalling
pathway(s) than ANP are involved in antioxidative properties
of OT. On the other hand, OT receptor activation and NO
production have a significant role in this effect of oxytocin.
Nitric oxide can function as an in vivo antioxidant [20]; hence,
OT, through NO, may function as an effective antioxidant.
OT-induced infarct size reduction was reversed by anantin
and L-NAME. These results may imply that infarct size
reduction in response to oxytocin mediated by OT/ANP/
NO pathway, as it was previously demonstrated that OT
leads to the release of ANP, which then stimulates the NO
production [9]. In agreement, Okawa et al. demonstrated that
NO is involved in the ANP induced infarct size reducing
effect through NO-mitochondrial ATP-sensitive K+ (mKATP)
channel-dependent pathway [21].
However, in the control group, both regional coronary
occlusion and its reperfusion induced ventricular arrhythmia,
reperfusion of the ischaemic myocardium led to less
severity of arrhythmias in all groups under study. The
results of the present study showed that OT completely
prevented episodes of VF induced both in occlusion and
reperfusion period. Oxytocin significantly decreased PVC
and lowered the arrhythmias severity index compared
with control and prevented VT in occlusion period. Treat-
ment with atosiban abolished OT-reduced arrhythmia,
indicating a receptor-mediated effect. Our data also
revealed that blockade of ANP and NO pathway(s) abol-
ished this antiarrhythmic effect. This finding demonstrates
the role of ANP and NO system on the anti-arrhythmic
effects of OT during both ischaemia and reperfusion
phases. Although drug (atosiban, anantin and L-NAME) pre-
treatment prevented OT effects and increased the severity
of lethal arrhythmias during ischaemia and reperfusionperiods, the major effect was observed in ischaemia phase
as significant increase in VT and VF. On the other hand, since
during the reperfusion, VF was increased by anantin, we
assume that ANP pathway plays an important role in anti-
VF effects of OT.
It seems that anti-lipid peroxidation property of OT, func-
tioning as an antioxidant is not the cause of antifibrillation
effect, because natriuretic peptide is not involved in this OT
action. In contrast to ANP, nitric oxide not only eliminated
the anti-lipid peroxidation effect of oxytocin but also
decreased the production of fibrillation. Since anti-VF effect
of oxytocin appears to be independent of lipid peroxidation,
thus, possibly, anti-lipid peroxidation, anti-arrhythmic and
anti-ischaemic effects of OT induced by different pathways
(or mechanisms).
In addition, the cardioprotective action of ANP in I/R injury
was shown to be mediated through the nitric oxide [21],
elevation of cGMP levels [22] and by PKC, PKG dependent
transduction mechanisms [21,23] followed by mKATP channel
activation. Okawa et al. also demonstrated that preischaemic
infusion of synthetic ANP has myoprotective effects against
I/R through NO- mKATP channel-dependent pathway [21].
Then, it is possible that OT effect on mKATP channels [24] was
indirect and comes from the ANP action on this channel.
Further studies are required to discriminate the specific role
of OT and ANP in mediating KATP channel activity.
Based on our observation, anantin abolished OT effects
through blockade of NPR-A receptor activation, which is
coupled to an increase in the intracellular concentration of
cGMP. Thus, decreased cGMP generation by inhibition of
NPR-A receptor may be involved in abolishing OT precon-
ditioning. However, the literature has proposed an involve-
ment of cGMP as a messenger in multiple physiologic actions
of OT [1], but the data obtained in this study do not allow us
to conclude the involvement of cGMP-mechanism in the
OT- precondition effect.
Additionally, intracardiac OT is essential for basal release
of ANP in the heart [6] and OT receptors are associated with
the ANP-cGMP and NO-cGMP pathways, which reduce the
force and rate of contraction and increase vasodilatation [1].
Since no significant differences were observed between the
two groups of ANA+OT and L-NAME+OT in infarct size and
ventricular arrhythmia, it is possible that OT exerts cardio-
protective effects through OT/ANP/NO pathways. In addi-
tion, unlike L-NAME, anantin cannot change the effect of
oxytocin in reducing lipid peroxidation. Therefore, the pos-
sible mechanism of OT/ANP/NO pathway is not involved
in both the anti-ischaemic and anti-lipid peroxidation effects
of oxytocin. Hence, based on our findings, it seems that OT
exerts cardioprotective effects through OT/ANP/NO and
OT/NO pathway independently; however, further investi-
gations are needed.
Conclusion
Although further studies are needed to clarify the contribu-
tion of other transduction pathways or mechanisms, our
ANP involvement in OT protection 93findings indicate that OT exerts its protective effect through
ANP pathway and also via attenuating lipid peroxidation.Acknowledgments
This study was financially supported by the grant no. 82 from
Tehran University of Medical Sciences.
References
[1] Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, func-
tion, and regulation. Physiol Rev 2001;81(2):629–83.
[2] Gutkowska J, Jankowski M, Mukaddam-Daher S, McCann S. Oxytocin is
a cardiovascular hormone. Braz J Med Biol Res 2000;33(6):625–33.
[3] Houshmand F, Faghihi M, Zahediasl S. Biphasic protective effect of
oxytocin on cardiac ischemia/reperfusion injury in anaesthetized rats.
Peptides 2009;30(12):2301–8.
[4] Favaretto A, Ballejo G, Albuquerque-Araujo W, Gutkowska J, Antunes-
Rodrigues J, McCann S. Oxytocin releases atrial natriuretic peptide from
rat atria in vitro that exerts negative inotropic and chronotropic action.
Peptides 1997;18(9):1377–81.
[5] Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH,
McCann SM. Oxytocin releases atrial natriuretic peptide by combining
with oxytocin receptors in the heart. Proc Natl Acad Sci USA 1997;94
(21):11704–9.
[6] Haanwinckel M, Elias L, Favaretto A, Gutkowska J, McCann S, Antunes-
Rodrigues J. Oxytocin mediates atrial natriuretic peptide release and
natriuresis after volume expansion in the rat. Proc Natl Acad Sci USA
1995;92(17):7902–6.
[7] Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in
cardioprotection. Cardiovasc Res 2006;69(2):318–28.
[8] Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their recep-
tors, and cyclic guanosine monophosphate-dependent signaling func-
tions. Endocr Rev 2006;27(1):47–72.
[9] de los Angeles Costa M, Bosc LVG, Majowicz MP, Vidal NA, Balaszczuk
AM, Arranz CT. Atrial natriuretic peptide modifies arterial blood pressure
through nitric oxide pathway in rats. Hypertension 2000;35(5):1119–23.
[10] Walker M, Curtis M, Hearse D, Campbell R, Janse M, Yellon D, et al. The
Lambeth Conventions: Guidelines for the study of arrhythmias in ischae-
mia, infarction, and reperfusion. Cardiovasc Res 1988;22(7):447–55.
[11] Curtis M, Walker M. Quantification of arrhythmias using scoring sys-
tems: an examination of seven scores in an in vivo model of regional
myocardial ischaemia. Cardiovasc Res 1988;22(9):656–65.[12] Weber W, Fischli W, Hochuli E, Kupfer E, Weibel E. Anantin–a peptide
antagonist of the atrial natriuretic factor (ANF). I. Producing organism,
fermentation, isolation and biological activity. J Antibiot (Tokyo) 1991;44
(2):164–71.
[13] Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J.
Oxytocin induces differentiation of P19 embryonic stem cells to cardio-
myocytes. Proc Natl Acad Sci USA 2002;99(14):9550–5.
[14] Chowdrey H, Curtis MJ, Hearse DJ. Effects of atrial natriuretic peptide
on ischaemia-induced arrhythmias in the rat heart: arrhythmogen or
endogenous antiarrhythmic agent? J Cardiovasc Pharmcol 1989;13(3):
451–4.
[15] Takata Y, Hirayama Y, Kiyomi S, Ogawa T, Iga K, Ishii T, et al. The
beneficial effects of atrial natriuretic peptide on arrhythmias and myo-
cardial high-energy phosphates after reperfusion. Cardiovasc Res 1996;
32(2):286–93.
[16] Kim HS, Kwack SJ, Lee BM. Lipid peroxidation, antioxidant enzymes,
and benzo [a] pyrene-quinones in the blood of rats treated with benzo [a]
pyrene. Chem Biol Interact 2000;127(2):139–50.
[17] Biyikli NK, Tugtepe H, Sener G, Velioglu-Ogunc A, Cetinel S, Mid-
illioglu S, et al. Oxytocin alleviates oxidative renal injury in pyelone-
phritic rats via a neutrophil-dependent mechanism. Peptides 2006;27
(9):2249–57.
[18] Szeto A, Nation DA, Mendez AJ, Dominguez-Bendala J, Brooks LG,
Schneiderman N, et al. Oxytocin attenuates NADPH-dependent super-
oxide activity and IL-6 secretion in macrophages and vascular cells. Am J
Physiol Endocrinol Metab 2008;295(6). E1495–E501.
[19] Tugtepe H, Sener G, Biyikli NK, Yuksel M, Cetinel S, Gedik N, et al. The
protective effect of oxytocin on renal ischemia/reperfusion injury in rats.
Regul Pept 2007;140(3):101–8.
[20] Yao Z, Gross GJ. Role of nitric oxide, muscarinic receptors, and the ATP-
sensitive K + channel in mediating the effects of acetylcholine to mimic
preconditioning in dogs. Circ Res 1993;73(6):1193–201.
[21] Okawa H, Horimoto H, Mieno S, Nomura Y, Yoshida M, Sasaki S.
Preischemic infusion of alpha-human atrial natriuretic peptide elicits
myoprotective effects against ischemia reperfusion in isolated rat hearts.
Mol Cell Biochem 2003;248(1):171–7.
[22] D’souza SP, Yellon DM, Martin C, Schulz R, Heusch G, Onody A, et al. B-
type natriuretic peptide limits infarct size in rat isolated hearts via KATP
channel opening. Am J Physiol Heart Circ Physiol 2003;284(5). H1592–
H600.
[23] Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide
administered just prior to reperfusion limits infarction in rabbit hearts.
Basic Res Cardiol 2006;101(4):311–8.
[24] Alizadeh AM, Faghihi M, Sadeghipour HR, Mohammad Ghasemi F,
Imani A, Houshmand F, et al. Oxytocin protects rat heart against ische-
mia-reperfusion injury via pathway involving mitochondrial ATP-
dependent potassium channel. Peptides 2010;31(7):1341–5.
